BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

InterMune, Inc. 

3280 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-466-2200 Fax: 415-466-2329


SEARCH JOBS

View Clinical Trials from BioPharm Insight

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.

For additional information about InterMune and its R&D pipeline, please visit: www.intermune.com


 Key Statistics


Email:
Ownership: Public

Web Site: InterMune, Inc.
Employees:
Symbol: ITMN
 




Segment
Drug Discovery





 Company News
InterMune, Inc. (ITMN) Wins FDA Approval For Lung Drug At Center Of Roche (RHHBY) Deal 10/15/2014 3:16:10 PM
Roche (RHHBY) Purchases Shares In Tender Offer For InterMune, Inc. (ITMN) 9/29/2014 8:45:53 AM
InterMune, Inc. (ITMN) Reports Memorandum Of Understanding In Connection With Consolidated Delaware Action 9/23/2014 7:39:53 AM
InterMune, Inc. (ITMN) Announces Anticipated Fundamental Change For 5.00% Convertible Senior Notes Due 2015 9/5/2014 12:52:44 PM
InterMune, Inc. (ITMN) CEO: Bittersweet Ending To A Biotech Comeback Story 8/26/2014 6:33:46 AM
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune, Inc. (ITMN), Pledges To Keep Employees 8/24/2014 7:38:32 PM
InterMune, Inc. (ITMN) Goes Up On The Block; GlaxoSmithKline (GSK), Roche (RHHBY), Sanofi (France) (SAN.PA) Line Up 8/14/2014 6:09:07 AM
InterMune, Inc. (ITMN) Reports Second Quarter 2014 Financial Results And Business Highlights 8/7/2014 8:29:51 AM
InterMune, Inc. (ITMN) To Release Second Quarter Financial Results On August 6 7/28/2014 8:41:32 AM
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/17/2014 10:50:06 AM
12345678910...